Evidence map›Paper›PMID 27034676›Full record

ReviewAdvances in hematology2016

Review on Haploidentical Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies.

William A Fabricius, Muthalagu Ramanathan

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in hematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03689907 (Assessing the Predictive Potential of Early Chimerism Analysis Following Allogeneic Stem-Cell Transplant), which is not on this map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03689907 completednot on this mapstarted 2019, after this paper: background citation

Assessing the Predictive Potential of Early Chimerism Analysis Following Allogeneic Stem-Cell Transplant

TypeobservationalSponsorDartmouth-Hitchcock Medical CenterRan2019 to 2024Enrolled40ConditionsAllogeneic Stem-Cell TransplantArmsChimerism Evaluation
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Mindfulness, Experiential Avoidance, and Recovery From Hematopoietic Stem Cell Transplantation.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2019
    Article
  16. Article
  17. Article
  18. Review
  19. Reactive oxygen species in haematopoiesis: leukaemic cells take a walk on the wild side.Journal of experimental & clinical cancer research : CR · 2018
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

William A FabriciusDivision of Hematology-Oncology, Bone Marrow Transplant Service, Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue N., Worcester, MA 01655, USA.
Muthalagu RamanathanDivision of Hematology-Oncology, Bone Marrow Transplant Service, Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue N., Worcester, MA 01655, USA.
University of Massachusetts Chan Medical School · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogenic hematopoietic cell transplantation (HSCT) is typically the preferred curative therapy for adult patients with acute myeloid leukemia, but its use has been reduced as a consequence of limited donor availability in the form of either matched-related donors (MRD) or matched-unrelated donors (MUD). Alternative options such as unrelated umbilical cord blood (UCB) transplantation and haploidentical HSCT have been increasingly studied in the past few decades to overcome these obstacles. A human leukocyte antigen- (HLA-) haploidentical donor is a recipient's relative who shares an exact haplotype with the recipient but is mismatched for HLA genes on the unshared haplotype. These dissimilarities pose several challenges to the outcomes of the patient receiving such a type of HSCT, including higher rates of bidirectional alloreactivity and graft failure. In the past 5 years, however, several nonrandomized studies have shown promising results in terms of graft success and decreased rates of alloreactivity, in part due to newer grafting techniques and graft-versus-host disease (GVHD) prophylaxis. We present here a summary and review of the latest results of these studies as well as a brief discussion on the advantages and challenges of haploidentical HSCT.

Identifiers

PMID27034676
PMCPMC4789357
OpenAlexW2289485549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.